Dossier assessment
Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) – Benefit assessment according to §35a Social Code Book (SGB) V
Report documents
-
Extract of dossier assessment
Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) – Benefit assessment according to §35a Social Code Book (SGB) V
-
Dossier assessment
Elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil (HIV-1 in adolescents) – Benefit assessment according to §35a Social Code Book (SGB) V
Dossier assessment
HIV-1-infected adolescents
No study data; added benefit not proven in comparison with the appropriate comparator therapy
Additional information
Federal Joint Committee (G-BA)
2018-05-03 A G-BA decision was published.
Project details
- Project no.
- A17-59
- Commission
- Commission awarded on 16.11.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Children's and adolescents' health
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed